New: CML Expert Videos


We have edited presentations from CML ONE 2021 on topics relevant to the Think Test Treat programme, creating short highlights videos, each 5–10 minutes in duration. Simona Soverini has also provided a dedicated video on the relevance of monitoring BCR-ABL1 kinetics versus key milestone measurements.

Dragana Milojkovic

Hammersmith Hospital,
London, UK

Importance of consistent adherence to the ELN recommendations

Re-cap the recommendations for BCR-ABL1 monitoring and to what extent these are being adhered to in the UK and other countries. Find out more about potential barriers to BCR-ABL1 monitoring and the clinical impact of poor monitoring on patients

Simona Soverini

University of Bologna,
Bologna, Italy

BCR-ABL1 transcript monitoring: Milestone measurements versus kinetics

Understand the dual importance of monitoring both molecular response at defined milestones and BCR-ABL1 transcript kinetics, including early kinetics in months 1–3 after TKI initiation, which can predict treatment outcomes and likelihood to achieve sustained TFR

Hugues de Lavallade

Guy's and St Thomas' Hospital,
London, UK

Prognostic value of low-level BCR-ABL1 mutations

Appreciate how NGS is now enabling us to detect low-level mutations and how this can provide an early indication of prognosis for each patient


Visualise how screening for low-level mutations at 3, 6 and 12 months using NGS can help guide early clinical intervention, to potentially prevent the emergence of predominant mutant subclones and reduce the likelihood of disease progression

Thomas Lion

LabDia Labordiagnostik &
St Anna Children’s Cancer Research Institute
Vienna, Austria

Relevance of BCR-ABL1 compound mutations

Acknowledge the challenge posed by compound mutations in BCR-ABL1 and how monitoring can guide selection of the appropriate TKI compound and dose

Predictive value of additional chromosomal abnormalities

Explore the role and importance of cytogenetic analysis today and how timely screening of additional chromosomal abnormalities can potentially limit their impact on disease course

All AEs should be reported to the Global Medical Information Call Center by phone: +800 000 27423
(for local numbers see
Alternatively, you can report AEs by email:

For more information, please contact Incyte Medical Information: